Pre-Open Stock Movers 04/22: (IMUX) (SNAP) (CMG) Higher; (VBIV) (IBKR) (BIIB) Lower (more...)

Today's Pre-Open Stock Movers:

Immunic, Inc. (Nasdaq: IMUX) 62.3% HIGHER; reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with coronavirus disease 2019 (COVID-19). In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These positive results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics.

VBI Vaccines Inc. (NASDAQ: VBIV) 28.2% LOWER; commenced an underwritten public offering of its common shares. VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Snap (NYSE: SNAP) 18.8% HIGHER; reported Q1 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $462 million versus the consensus estimate of $431.43 million. DAUs were 229 million in Q1 2020, an increase of 39 million or 20% year-over-year.

Compugen Ltd. (Nasdaq: CGEN) 12.5% HIGHER; announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer. Roth Capital initiates coverage with a Buy rating and a price target of $28.00.

USANA Health Sciences (NYSE: USNA) 10% HIGHER; reported Q1 EPS of $1.23, $0.40 better than the analyst estimate of $0.83. Revenue for the quarter came in at $266.6 million versus the consensus estimate of $240.68 million. USANA Health Sciences sees FY2020 EPS of $4.00-$4.90, versus the consensus of $4.01. USANA Health Sciences sees FY2020 revenue of $1-1.08 billion, versus the consensus of $1.01 billion.

Chipotle Mexican Grill (NYSE: CMG) 8.6% HIGHER; reported Q1 EPS of $3.08, $0.18 better than the analyst estimate of $2.90. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.42 billion.

Teradyne (NASDAQ: TER) 8.3% HIGHER; reported Q1 EPS of $1.00, $0.12 better than the analyst estimate of $0.88. Revenue for the quarter came in at $704 million versus the consensus estimate of $678.81 million. Teradyne sees Q2 2020 EPS of $0.86-$1.16, versus the consensus of $0.80. Teradyne sees Q2 2020 revenue of $690-800 million, versus the consensus of $646.81 million.

GameStop (NYSE: GME) 7.1% HIGHER; did not make a portion of certain lease payments

Expedia (NASDAQ: EXPE) 7% HIGHER; Reports from the WSJ that the company is in advanced talks to sell a stake to private-equity firms Silver Lake Partners and Apollo Global Management Inc (NYSE: APO) for about $1 billion.

Interactive Brokers Group, Inc. (NASDAQ: IBKR) 6.2% LOWER; noted that, as has been widely reported, the energy markets yesterday exhibited extraordinary price activity in the New York Mercantile Exchange (NYMEX) West Texas Intermediate Crude Oil contract. The price of the May 2020 contract dropped to an unprecedented negative price of $37.63. This price was the basis for determining the settlement price for cash-settled contracts traded on the CME Globex and also on a separate, expiring cash-settled futures contract listed on the Intercontinental Exchange Europe (“ICE Europe”). Several Interactive Brokers LLC (“IBLLC”) customers held long positions in these CME and ICE Europe contracts, and as a result they incurred losses in excess of the equity in their accounts. IBLLC has fulfilled the firm’s required variation margin settlements with the respective clearinghouses on behalf of its customers. As a result, the Company has recognized an aggregate provisionary loss of approximately $88 million.

Biogen (NASDAQ: BIIB) 5.9% LOWER; reported Q1 EPS of $9.14, $1.40 better than the analyst estimate of $7.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.41 billion. Stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.

Exact Sciences (NASDAQ: EXAS) 4.6% HIGHER; sees total revenue of approximately $348M, compared to $162M, versus the consensus of $343 million.

Quotient Limited (NASDAQ: QTNT) 3.5% HIGHER; reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ COVID-19 Antibody Microarray as a research-use-only (RUO) product in Europe and the US.

Navient (NASDAQ: NAVI) 2.9% LOWER; reported Q1 EPS of $0.46, $0.14 worse than the analyst estimate of $0.60.

United Airlines Holdings, Inc. (NASDAQ: UAL) 2.4% LOWER; announced an underwritten public offering of 39,250,000 shares of its common stock, subject to market conditions and other factors. Morgan Stanley and Barclays are acting as the underwriters of the offering. The Company has also granted to the underwriters a 30-day option to purchase up to 3,925,000 additional shares. The proceeds from the offering will be used for general corporate purposes.

Texas Instruments (NASDAQ: TXN) 2.3% HIGHER; reported Q1 EPS of $1.24, may not compare to the analyst estimate of $1.00. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.17 billion. Earnings per share include a 10-cent benefit for items that were not in the company's original guidance. Texas Instruments sees Q2 2020 EPS of $0.64-$1.04, versus the consensus of $0.99. Texas Instruments sees Q2 2020 revenue of $2.61-3.19 billion, versus the consensus of $3.15 billion.

Netflix (NASDAQ: NFLX) 1.7% LOWER; reported Q1 EPS of $1.57, $0.08 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $5.77 billion versus the consensus estimate of $5.76 billion. The company posted global streaming paid net additions of 15.77 million, versus 7 million the company previously expected. The company now has 182.86 million global streaming paid members. The company sees Q2 revenues of $6.048 billion, versus the consensus of $5.97 billion. They see Q2 EPS of $1.81 versus the consensus of $1.54. The company sees Q2 global streaming paid net additions of 7.5 million.

You May Also Be Interested In

• Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
• After-hours movers: Meta, Ford, IBM, ServiceNow and more
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition